NeuPath Health (TSXV:NPTH) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NPTH NeuPath Health Inc TSXV:NPTH
39 GF Score
Price C$0.55
GF Value C$0.25
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is NeuPath Health Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

NeuPath Health Valuation Rank Related Terms

TSXV:NPTH
39GF Score
NeuPath Health Inc TSXV:NPTH
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NeuPath Health (TSXV:NPTH) Overvalued in 2026?

Based on GuruFocus' analysis, NeuPath Health stock appears to be overvalued. The current stock price of C$0.55 is trading 120% above its estimated GF Value™ of C$0.25. GuruFocus considers NeuPath Health to be Significantly Overvalued.

Key valuation signals for TSXV:NPTH:

  • Valuation Rank:
  • GF Value™: C$0.25 vs. price of C$0.55 (120% above fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the TSXV:NPTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeuPath Health Business Description

Address 181 Bay Street, Suite 2100, Toronto, ON, CAN, M5J 2T3
NeuPath Health Inc operates an end-to-end, integrated network of healthcare businesses. It utilizes research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by acute and chronic musculoskeletal conditions, including chronic pain, spinal injuries, sports-related injuries, and concussions. It operates an interdisciplinary network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of healthcare providers. Its medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal or back injuries, sports-related injuries, and concussions. The company operates in one industry segment: medical services.
39GF Score

Get the complete analysis for TSXV:NPTH

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.55
Price
C$0.25
GF Value